Abstract:Rationale: Genetic editing has shown great potential for the treatment of human hereditary disorders via the elimination of mutations in embryos. However, the efficiency and safety of germline gene editing are not well understood. Objective: We aimed to examine the preclinical efficacy/safety of embryonic base editing in a mouse model of hypertrophic cardiomyopathy (HCM) using a novel adenine base editor (ABE) platform. Methods and Results: Here, we described the use of an ABEmax-NG to directly correct the pathogenic R404Q/+ mutation (Myh6 c.1211C>T) in embryos for a mouse model of HCM, increasing the number of wild-type embryos for in vitro fertilization. Delivery of the ABEmax-NG mRNA to embryos from R404Q/+ HCM mice resulted in 62.5-70.8% correction of the Myh6 c.1211C>T, reducing the level of mutant RNA and eliminating HCM in the post-natal mice as well as their offspring. In addition, the same sgRNA was also used to target an intronic locus (TGG PAM) with an overall editing rate of 86.7%, thus confirming that ABEmax-NG can efficiently edit target loci with different PAMs (NG) and genomic distribution in vivo. Compared with CRISPR/ssODN-mediated correction, ABEmax-NG displayed a much higher correction rate without introducing indels. DNA and RNA off-target analysis did not detect off-target editing in treated embryos and founder mice. In utero injection of adeno-associated virus 9 (AAV9) encoding the ABEmax-NG also resulted in around 25.3% correction of the pathogenic mutation and reduced of mutant RNA, thereby indicating ABEmax-NG has the potential to correct the HCM mutation in vivo. Conclusions: We developed an ABEmax-NG system, which efficiently corrected a pathogenic Myh6 HCM mutation in mouse embryos without off target lesions, thus safely eliminating HCM in derived mice and their progeny.

Cost-effective Generation of A-to-G Mutant Mice by Zygote Electroporation of Adenine Base Editor Ribonucleoproteins.

Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration

Development of a Highly Efficient Prime Editor System in Mice and Rabbits.

Improved Prime Editors Enable Pathogenic Allele Correction and Cancer Modelling in Adult Mice

Improved split prime editors enable efficient in vivo genome editing

Genetic Modification of Mice Using Prime Editing

A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver

Effective Gene Editing by High-Fidelity Base Editor 2 in Mouse Zygotes

Mini-PE, a prime editor with compact Cas9 and truncated reverse transcriptase

Development Of Highly Efficient Dual-Aav Split Adenosine Base Editor For In Vivo Gene Therapy

Efficient prime editing in two-cell mouse embryos using PEmbryo

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

An Optimized Prime Editing System for Efficient Modification of the Pig Genome.

Efficient prime editing in mouse brain, liver and heart with dual AAVs

A split prime editor with untethered reverse transcriptase and circular RNA template

Highly efficient prime editing by introducing same-sense mutations in pegRNA or stabilizing its structure

Electroporation-mediated genome editing in vitrified/warmed mouse zygotes created by IVF via ultra-superovulation

Human cleaving embryos enable robust homozygotic nucleotide substitutions by base editors

Adenine Base Editing in vivo with a Single Adeno-Associated Virus Vector

Feasibility for a large scale mouse mutagenesis by injecting CRISPR/Cas plasmid into zygotes

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG